NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









X-ZELL

X-ZELL

Private
SingaporeHealthcare & Life Scienceshttps://www.x-zell.com/

Last Round

Grant

Nov 18, 2020

Est. Valuation

$1.71M

Total Funding Raised

$4.14M

Company Overview

X-ZELL is a medical technology company that develops next-generation cytology platforms for the detection, visualization, and digitization of atypical cells in minimally invasive body liquids.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices, Precision Medicine

Business Model

B2B

Customer Profile

Hardware Sales, Usage-Based SaaS, Services & Consulting

AI Layer

Application

Keywords

cell-based diagnosticsmultiplex antibody panelsrare cell analysisliquid biopsypathology diagnosticsdigital pathologyoncology diagnosticscytology workflowin vitro diagnosticsIVDAI pathologymedical deviceprecision medicinebiotech lab toolsOEM manufacturing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

X-ZELL Comparables

Compare X-ZELL with similar companies based on industry and business-model similarity.

X-ZELL comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
RareCyte
81%
ScreenCell
78%
Menarini Group
76%

X-ZELL Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantNov 18, 2020
SeedOct 15, 2020
AcceleratorMar 23, 2015

Key People

Founding team and executive leadership

Johannes Hille

Chief Executive Officer (CEO)

Executive Team

Sebastian C. P. Bhakdi

CEO, Group CEO

Executive Team

X-ZELL Investors

Notable investors and investment history

X-ZELL investors
InvestorRounds
Startup SGGrant
Essex Bio-TechnologySeed
MedTech InnovatorGrant
Deutsche IndustrieanlagenSeed
Y CombinatorAccelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 1, 2026

    Commercial launch of Cryophore multiplex antibody panels on March 1, 2026.

X-ZELL Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

X-ZELL Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about X-ZELL's valuation, stock price, and market status.

Firmographic Details

HeadquartersSingapore
Employee Range19
Year Founded2014
Last FundingNov 18, 2020

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.